Last updated: 16 March 2020 at 7:42pm EST

David Louis Johnson Net Worth




The estimated Net Worth of David Louis Johnson is at least 991 千$ dollars as of 22 February 2020. David Johnson owns over 22,000 units of Dynavax Technologies stock worth over 746,364$ and over the last 11 years David sold DVAX stock worth over 245,019$.

David Johnson DVAX stock SEC Form 4 insiders trading

David has made over 9 trades of the Dynavax Technologies stock since 2016, according to the Form 4 filled with the SEC. Most recently David exercised 22,000 units of DVAX stock worth 240,020$ on 22 February 2020.

The largest trade David's ever made was exercising 22,000 units of Dynavax Technologies stock on 22 February 2020 worth over 240,020$. On average, David trades about 3,679 units every 51 days since 2014. As of 22 February 2020 David still owns at least 68,411 units of Dynavax Technologies stock.

You can see the complete history of David Johnson stock trades at the bottom of the page.



What's David Johnson's mailing address?

David's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 900, EMERYVILLE, CA, 94608.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. HackPartners L P/Ilbiotechnolog...James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.



What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.



Complete history of David Johnson stock trades at Dynavax Technologies

インサイダー
取引
取引
合計金額
David Louis Johnson
Vice President
オプション行使 107,360$
22 Feb 2020
David Louis Johnson
Vice President
オプション行使 23,716$
5 Feb 2020
David Louis Johnson
Vice President
販売 187,508$
28 Feb 2019
David Louis Johnson
Vice President
オプション行使 51,276$
5 Feb 2019
David Louis Johnson
Vice President
オプション行使 137,250$
31 Dec 2018
David Louis Johnson
Vice President
オプション行使 77,118$
1 Feb 2018
David Louis Johnson
Vice President
販売 57,511$
4 Jan 2018
David Louis Johnson
Vice President
オプション行使 93,500$
31 Dec 2017
David Louis Johnson
Vice President
オプション行使 24,143$
5 Dec 2016


Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include: